Current Report Filing (8-k)
August 15 2018 - 9:09AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934.
Date of Report: August 15, 2018
(Date of earliest event reported)
Oragenics,
Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
FL
|
|
001-32188
|
|
59-3410522
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
|
|
4902 Eisenhower Boulevard, Suite 125
Tampa, FL
|
|
33634
|
(Address of principal executive offices)
|
|
(Zip Code)
|
813-286-7900
(Registrants telephone number, including area code)
Not Applicable
(Former
Name or Former Address, if changed since last report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or
Rule 12b-2 of
the Securities Exchange Act of
1934 (§240.12b-2 of
this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01
|
Regulation FD Disclosure.
|
On August 15, 2018, Oragenics, Inc. (the Company) plans to make an investor presentation (the Investor Presentation) a copy of
which is attached to this report as Exhibit 99.1 to this Current Report on Form
8-K
and is incorporated herein by reference. The Company also expects to use the Investor Presentation from time to time in
connection with presentations to potential investors, industry analysts and others. The Investor Presentation is available under the Presentations tab in the News and Media section of the Companys website, located at
www.oragenics.com
.
By filing this Current Report on Form
8-K
and furnishing the information contained
herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.
The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Companys
Securities and Exchange Commission (SEC) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the
information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through
other public disclosure.
The information presented in Item 7.01 of this Current Report on Form
8-K
and Exhibit
99.1 shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, unless the Company
specifically states that the information is to be considered filed under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
On August 15, 2018, the Company announced it was resuming its Phase 2 clinical trial of AG013 for the treatment of Oral Mucositis following positive
routine safety review. A copy of the press release announcing these events is attached as Exhibit 99.2 to this Current Report on Form
8-K
and is hereby incorporated by reference herein.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized on this 15
th
day of August, 2018.
|
|
|
ORAGENICS, INC.
(Registrant)
|
|
|
BY:
|
|
/s/ Michael Sullivan
|
|
|
Michael Sullivan
Chief Financial
Officer
|
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024